AU2020252191A1 - Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein - Google Patents

Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein Download PDF

Info

Publication number
AU2020252191A1
AU2020252191A1 AU2020252191A AU2020252191A AU2020252191A1 AU 2020252191 A1 AU2020252191 A1 AU 2020252191A1 AU 2020252191 A AU2020252191 A AU 2020252191A AU 2020252191 A AU2020252191 A AU 2020252191A AU 2020252191 A1 AU2020252191 A1 AU 2020252191A1
Authority
AU
Australia
Prior art keywords
seq
binding
domain
protein
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020252191A
Other languages
English (en)
Inventor
Godfrey Jonah Rainey
Jin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immetas Therapeutics Inc
Original Assignee
Immetas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immetas Therapeutics Inc filed Critical Immetas Therapeutics Inc
Publication of AU2020252191A1 publication Critical patent/AU2020252191A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020252191A 2019-04-01 2020-03-31 Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein Abandoned AU2020252191A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962827381P 2019-04-01 2019-04-01
US62/827,381 2019-04-01
PCT/US2020/025979 WO2020205875A1 (en) 2019-04-01 2020-03-31 Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein

Publications (1)

Publication Number Publication Date
AU2020252191A1 true AU2020252191A1 (en) 2021-11-18

Family

ID=72607367

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020252191A Abandoned AU2020252191A1 (en) 2019-04-01 2020-03-31 Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein

Country Status (9)

Country Link
US (1) US11718673B2 (https=)
EP (1) EP3947449A4 (https=)
JP (1) JP2022525238A (https=)
KR (1) KR20220004067A (https=)
CN (1) CN114127107B (https=)
AU (1) AU2020252191A1 (https=)
CA (1) CA3135838A1 (https=)
TW (1) TW202102539A (https=)
WO (1) WO2020205875A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021231773A1 (en) 2020-05-13 2021-11-18 Good Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
CA3201518A1 (en) * 2020-11-18 2022-05-27 Suzhou Transcenta Therapeutics Co., Ltd. Bi-functional molecules
CN121511262A (zh) * 2023-06-28 2026-02-10 北京哲源科技有限责任公司 靶向pd-l1和il-1的双特异性抗体及其用途
WO2025119346A1 (en) * 2023-12-07 2025-06-12 LaNova Medicines Limited Anp-dependent antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714738B1 (en) * 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
AU2014227638A1 (en) * 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
WO2015035365A1 (en) * 2013-09-09 2015-03-12 The Nohns Hopkins University Targeting the m2-tumor associated macrophage for cancer therapy
WO2016141387A1 (en) * 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EA201890790A1 (ru) * 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
WO2018049261A1 (en) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
WO2018119001A1 (en) 2016-12-19 2018-06-28 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
JP2020524694A (ja) * 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (en) * 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer

Also Published As

Publication number Publication date
TW202102539A (zh) 2021-01-16
WO2020205875A1 (en) 2020-10-08
EP3947449A1 (en) 2022-02-09
EP3947449A4 (en) 2022-09-07
CN114127107B (zh) 2024-11-01
CA3135838A1 (en) 2020-10-08
US20200308285A1 (en) 2020-10-01
CN114127107A (zh) 2022-03-01
KR20220004067A (ko) 2022-01-11
JP2022525238A (ja) 2022-05-11
US11718673B2 (en) 2023-08-08

Similar Documents

Publication Publication Date Title
JP7690552B2 (ja) ＣＤ１３７抗原結合部位を含むＦｃ結合断片
US20260001964A1 (en) Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof
US11718673B2 (en) Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein
CN112739379B (zh) 包含OX40抗原结合位点的Fc结合片段
Yoshio-Hoshino et al. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6–dependent tumor
TW201900672A (zh) 改良之抗原結合受體型式
CA3030837A1 (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
EP3388451A1 (en) Multi specific binding molecules targeting aberrant cells
TW202535924A (zh) 抗ｄｌｌ３嵌合抗原受體及其用途
CN112513077B (zh) 高效表达的egfr和pd-l1双特异性结合蛋白
JP2013520999A (ja) Ｃｄ５２に対するモノクローナル抗体
CN119053342A (zh) 用于亲合力受体交联和免疫调节的多特异性抗体
JP2023537225A (ja) 抗－ｌｉｌｒｂ１抗体およびその用途
JP2025134864A (ja) 抗ケモカイン様受容体１ヒト化抗体及びその治療適用
AU2020254215A1 (en) CD3 binding molecules
CA3150884A1 (en) Immune synapse-stabilizing chimeric antigen receptor (car) t cell
CN114746451A (zh) TGFβ/PD-L1双特异性结合蛋白
WO2024083226A1 (zh) 抗体融合蛋白及其制备和应用
CN116199778B (zh) 抗4-1bb抗体及其用途
CN120051563A (zh) 工程化免疫细胞
WO2022072697A2 (en) Bispecific binding molecules 2
WO2024085166A1 (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
WO2023186113A9 (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
EP4606823A1 (en) Synthetic t cell receptor antigen receptor specifically binding to lilrb4 and use thereof
RU2773655C2 (ru) Комбинация, содержащая перенаправляющие т-клетки многофункциональные антитела и модуляторы контрольных точек, и ее применения

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period